<DOC>
	<DOCNO>NCT02604433</DOCNO>
	<brief_summary>This Phase 3 , double-blind , randomize , placebo-controlled , multicenter study determine efficacy safety luspatercept ( ACE-536 ) plus Best supportive care ( BSC ) versus placebo plus BSC adult require regular red blood cell transfusion due ( β ) -thalassemia . The study divide Screening/Run-in Period , double-blind Treatment Period , double-blind Long-term Treatment Period , Post-treatment Follow-up Period .</brief_summary>
	<brief_title>An Efficacy Safety Study Luspatercept ( ACE-536 ) Versus Placebo Adults Who Require Regular Red Blood Cell Transfusions Due Beta ( β ) Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Male female , ≥ 18 year age time sign informed consent document ( ICF ) . 2 . Subject must understand voluntarily sign Inform Consent Form prior studyrelated assessments/procedures conduct . 3 . Subject willing able adhere study visit schedule protocol requirement . 4 . Documented diagnosis βthalassemia Hemoglobin E/βthalassemia . 5 . Regularly transfuse , define : 620 Red Blood Cell ( RBC ) unit 24 week prior randomization transfusionfree period ≥ 35 day period . 6 . Performance status : Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . 7 . A female childbearing potential ( FCBP ) study define female : 1 ) achieve menarche point , 2 ) undergone hysterectomy bilateral oophorectomy 3 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( ie , menses time precede 24 consecutive month ) . FCBP participate study must : Have two negative pregnancy test verify Investigator prior start study therapy . She must agree ongoing pregnancy test course study , end study treatment . This apply even subject practice true abstinence heterosexual contact . Either commit true abstinence heterosexual contact ( must review monthly basis source document ) agree use , able comply , effective contraception without interruption , 28 day prior start investigational product , study therapy ( include dose interruption ) , 12 week ( approximately five time mean terminal halflife luspatercept base multipledose Pharmacokinetic PK ) data ) discontinuation study therapy . 8 . Male subject must : Practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 12 week ( approximately five time mean terminal halflife luspatercept base multipledose PK data ) follow investigational product discontinuation , even undergone successful vasectomy . The presence follow exclude subject enrollment : 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Any condition confound ability interpret data study . 4 . A diagnosis Hemoglobin S/βthalassemia alpha ( α ) thalassemia ( eg , Hemoglobin H ) ; βthalassemia combine αthalassemia allow . 5 . Evidence active hepatitis C ( HCV ) infection , active infectious hepatitis B , know positive human immunodeficiency virus ( HIV ) . 6 . Deep Vein Thrombosis ( DVT ) stroke require medical intervention ≤ 24 week prior randomization . 7 . Chronic anticoagulant therapy ≤ 28 day prior randomization , Low Molecular Weight ( LMW ) heparin Sinus venous Thrombosis ( SVT ) chronic aspirin allow . 8 . Platelet count &gt; 1000 x 109/L 9 . Insulindependent diabetes , ie , chronic treatment insulin . 10 . Treatment another investigational drug device ≤ 28 day prior randomization . 11 . Prior exposure sotatercept ( ACE011 ) luspatercept ( ACE536 ) . 12 . Use erythropoiesisstimulating agent ( ESA ) ≤ 24 week prior randomization . 13 . Iron chelation therapy , initiate ≤ 24 week prior randomization ( allow initiate &gt; 24 week treatment ) . 14 . Hydroxyurea treatment ≤ 24 week prior randomization . 15 . Pregnant lactating female . 16 . Uncontrolled hypertension . Controlled hypertension protocol consider ≤ Grade 1 accord NCI Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 ( current active minor version ) . 17 . Major organ damage , include : Liver disease alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal ( ULN ) histopathological evidence liver cirrhosis/fibrosis liver biopsy ; Heart disease , heart failure classify New York Heart Association ( NYHA ) classification 3 high , significant arrhythmia require treatment , recent myocardial infarction within 6 month randomization . Lung disease , include pulmonary fibrosis pulmonary hypertension clinically significant . Creatinine clearance &lt; 60 mL/min ( per CockroffGault method ) . 18 . Proteinuria ≥ Grade 3 accord NCI CTCAE version 4.0 ( current active minor version ) . 19 . Adrenal insufficiency . 20 . Major surgery ≤ 12 week prior randomization ( subject must completely recover previous surgery prior randomization ) . 21 . History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational product ( see Investigator Brochure ) . 22 . Cytotoxic agent , immunosuppressant ≤ 28 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ACE-536</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Placebo</keyword>
	<keyword>Red Blood Cell Transfusions</keyword>
	<keyword>Beta -Thalassemia</keyword>
</DOC>